Luye Pharma   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Shanghai China (1994)
Status: No NME R&D (1994)

Organization Overview

First Clinical Trial
2008
NCT00606515
First Marketed Drug
2023
risperidone (risperdal)
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Luye Pharma | Luye Pharma. | Luye Pharma Group | Luye Pharma Group Ltd. | Luye Pharma US Ltd | Nanjing Luye Sike Pharmaceutical Co.,Ltd. | Shandong Boan Biotechnology Co., Ltd | Shan Dong Boan Biotechnology Co., Ltd | Shan Dong Boan Biotechnology Co., Ltd(Co-sponsor) | SHANDONG LUYE | Shandong Luye Pharmaceutical Co., Ltd. | Shangdon Boan Biotechnology Co Ltd | Shangdong Boan Biotechnology Co Ltd | Shang Dong Boan Biotechnology Co., Ltd (Co-sponsor)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 3)

Breast Neoplasms (Phase 4)

Carcinoma (Phase 4)

Carcinoma, Non-Small-Cell Lung (Phase 4)

Carcinoma, Squamous Cell (Phase 4)

Depression (Phase 1)

Depressive Disorder (Phase 1)

Depressive Disorder, Major (Phase 1)

Disease (Phase 1)

Esophageal Neoplasms (Phase 4)

Leukemia (Phase 3)

Leukemia, Lymphoid (Phase 3)

Lipid Metabolism Disorders (Phase 1)

Lung Neoplasms (Phase 4)

Macular Degeneration (Phase 3)

Metabolic Diseases (Phase 1)

Mood Disorders (Phase 1)

Neoplasms (Phase 4)

Parkinson Disease (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Prostatic Neoplasms (Phase 3)

Psychotic Disorders (Phase 1)

Schizophrenia (Phase 1)

Small Cell Lung Carcinoma (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 69
  • # of Trial APIs: 34